TNBC Samples | Order Biospecimens Online

Triple Negative Breast Cancer

Use the menu on the left side to filter for your ideal biospecimen

Triple Negative Breast Cancer (TNBC) accounts for approximately 10-20% of global breast cancer cases and is thought to be a very aggressive form that is larger in size and associated with a higher tumor grade. This type of cancer lacks the expression of estrogen, progesterone and, HER2 receptors which are crucial drug targets for the treatment of breast cancer. Consequently, patients often face poor prognoses as the options for therapeutic interventions are limited.
Central BioHub therefore aims to support researchers with human TNBC samples that can be utilized to discover new diagnostic and treatment methods. Scientists worldwide can directly access detailed information for our Triple Negative Breast Cancer samples prior to shipping, apply advanced filter options with our expert search, or browse our complete catalogue by clicking on CLINICAL DIAGNOSIS, ICD-10-CM CODES, and LABORATORY PARAMETERS.

Show rows
|< < of > >|

To expand the therapeutic options for breast cancer, scientists worldwide are using Triple Negative Breast Cancer (TNBC) samples from patients for research studies to enlighten the underlying pathology of TNBC and to discover additional markers that are urgently needed to better predict the patient’s outcome and guide treatment options.  
Central BioHub is the biggest online marketplace for human tissue samples worldwide and offers more than 300 Triple Negative Breast cancer tissue samples. All TNBC specimens were tested for multiple laboratory parameters and come along with detailed demographic donor profiles and clinical history records.  
Find Triple Negative Breast Cancer Samples that match your needs and reserve them online prior before checkout within a few clicks. If you need further assistance, our scientific employees will be happy to answer all your questions via mail, phone, or live chat at any time. 

Triple Negative Breast Cancer (TNBC) is a subtype of breast cancer that lacks the expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Therefore, hormonal or targeted therapies with drugs aiming these receptors cannot be considered as treatment.
TNBC is diagnosed by breast tissue biopsy where the presence of estrogen, progesterone and HER2 receptors is determined. Central BioHub offers TNBC tissue samples that had been tested histopathological and can be utilized by researchers worldwide to develop more fast and convenient diagnostic approaches.
Treatment options for TNBC include surgery to remove the tumor and chemotherapy or radiation therapy to target the breast cancer cells. By modulating the immune system with immune therapy, recognition and elimination of cancer cells by T-cells can be enhanced and improve the patient´s outcomes.
Currently, two PARP inhibitors have been approved for metastatic TNBC which targets the DNA repair pathways in cancer cells as well as immune checkpoint inhibitors for PD-1/PD-L1. Central BioHub is eager to push the boundaries for biomedical treatment options with our TNBC samples, that can be used by researchers to investigate and discover novel drug targets.